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http://www.nutritionandmetabolism.com/content/10/1/16RESEARCH Open AccessDietary supplementation with long-chain
monounsaturated fatty acids attenuates obesity-
related metabolic dysfunction and increases
expression of PPAR gamma in adipose tissue in
type 2 diabetic KK-Ay mice
Zhi-Hong Yang*, Hiroko Miyahara, Yusuke Iwasaki, Jiro Takeo and Masashi KatayamaAbstract
The objective of present study was to examine the effect of long-chain monounsaturated fatty acids (LC-MUFAs)
with chain lengths longer than 18 (i.e., C20:1 and C22:1 isomers combined) on obesity-related metabolic
dysfunction and its molecular mechanisms. Type-2 diabetic KK-Ay mice (n = 20) were randomly assigned to the 7%
soybean oil-diet group (control group) and 4% LC-MUFA concentrate-supplemented-diet group (LC-MUFA group).
At 8 weeks on the diet, the results showed that plasma, liver and adipose tissue levels of C20:1 and C22:1 isomers
increased significantly with LC-MUFA treatment. Supplementation with LC-MUFAs markedly reduced white fat pad
weight as well as adipocyte size in the mice. The levels of plasma free fatty acids, insulin, and leptin concentration
in the obese diabetic mice of the LC-MUFA group were also decreased as compared with the mice in the soybean
oil-diet control group. Dietary LC-MUFAs significantly increased the mRNA expression of peroxisome
proliferator-activated receptor gamma (Pparg), lipoprotein lipase (Lpl), fatty acid transport protein (Fatp), fatty acid
translocase/CD36 (Cd36), as well as mRNA expression of genes involved in lipid oxidation such as carnitine
palmitoyltransferase-1A (Cpt1a) and citrate synthase (Cs), and decreased the mRNA expression of inflammatory
marker serum amyloid A 3 (Saa3) in the adipose tissues of diabetic mice. The results suggest that LC-MUFAs may
ameliorate obesity-related metabolic dysfunction partly through increased expression of Pparg as well as its target
genes, and decreased inflammatory marker expression in white adipose tissue.
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Type 2 diabetes mellitus (DM) is a major global health
problem and one of the major causes of morbidity and
mortality. The condition is increasing in epidemic pro-
portions in both developed and developing nations; it is
estimated that there were 11 million diabetic patients in
the United States in the year 2000, and the number is
expected to increase to 29 million by 2050 [1-3]. The
pathogenesis of type 2 DM is complex, involving pro-
gressive development of insulin resistance in peripheral
tissues accompanied by defective insulin secretion from* Correspondence: yangzh@nissui.co.jp
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reproduction in any medium, provided the orpancreatic beta cells leading to overt hyperglycemia [4].
The development of type 2 DM is caused by a combin-
ation of lifestyle and genetic factors, and the rising levels
of obesity and fat accumulation as a result of a positive
calorie balance is thought to be in part related to the epi-
demiology of type 2 DM [1]. Numerous lines of evidence
support the involvement of fatty acids in type 2 DM, and
many studies have demonstrated that fatty acids with
different degrees of saturation have different effects on in-
sulin sensitivity and glucose/lipid metabolism [5,6]. Com-
pared with saturated fatty acids, increasing evidence has
indicated favorable effects of monounsaturated fatty acids
(MUFAs) on both obesity and DM [7-10]. On the other
hand, the MUFA used in these studies was almost alwaysd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Major fatty acid composition (%) of dietary oils
Fatty acid Soybean oil LC-MUFA concentrate
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MUFAs of greater chain length (> C18) have beneficial
effects on obesity-related DM. Study of Greenland Eskimos
shows their high consumption of food rich in n-3 polyun-
saturated fatty acids (n-3 PUFAs) as well as long-chain
MUFAs (LC-MUFAs; i.e., C20:1 and C22:1), suggesting
a possible correlation between LC-MUFA intake and
reduced risk of obesity-related disease [11,12]. Consistently
high levels of LC-MUFAs are found in the lipids of some
pelagic surface fish species, such as saury [13], capelin [14],
sprats [15], and herring [16], whose lipids originate from
their food source, which includes zooplankton [17,18]. We
previously reported that ingestion of LC-MUFA-rich fish
oils such as saury oil [19] and pollock oil [20] attenuates
metabolic syndrome risk factors by decreasing plasma glu-
cose and lipid levels in diet-induced obese mice. On the
other hand, besides LC-MUFAs, saury and pollock oils are
also rich in n-3 PUFAs such as eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), and therefore, it
is not clear whether these protective effects were directly
attributable to LC-MUFAs. To investigate the effects of
LC-MUFAs on metabolic syndrome, we further produced
a LC-MUFA concentrate derived from saury oil, and found
that the LC-MUFA–supplemented diet also improved
symptoms of metabolic syndrome in diet-induced obese
mice [21]. However, it remains unknown whether dietary
LC-MUFAs ameliorate obesity-related metabolic dysfunc-
tions in experimental animals with type 2 DM.
KK-Ay mice, also known as Yellow KK obese mice, carry
both lethal yellow obese (Ay) and diabetic genes, and they
show severe obesity, hypertriglyceridemia, hyperglycemia,
hyperinsulinemia, and glucose intolerance by 8 weeks of
age [22,23]. Therefore, they are widely used as a good
experimental model for obesity and type 2 DM. In the
current study, we examined the effect of LC-MUFA intake
on diabetic risk factors in KK-Ay mice and further investi-





C18:2 n-6 55.1 0.8
C18:3 n-3 7.6 0.2
C20:1 n-11 ND 16.8
C20:1 n-9 ND 4.7
C22:1 n-11 ND 34.8
C22:1 n-9 ND 1.5
C20:5 n-3 ND 0.2
C22:5 n-3 ND 0.2
C22:6 n-3 ND 0.5
ND: Not detected.Methods
Animals and diets
All animal experiments were conducted in complete com-
pliance with the National Institutes of Health’s “Guide for
the Care and Use of Laboratory Animals” and were
approved by the Institutional Animal Care and Use
Committee at Nihon Bioresearch Inc. (Gifu, Japan), where
the animals were housed for the entire experimental
period. Five-week-old spontaneously diabetic male KK-Ay
mice were obtained from CLEA Japan Inc. (Shizuoka,
Japan). Mice were housed one per cage at 23 ± 1°C with a
12-h light/dark cycle and provided free access to water
and standard mouse chow CRF-1 (Oriental Yeast Co.,
Ltd., Tokyo, Japan) for an acclimatization period of 1
week.The fatty acid composition of the dietary oils is shown
in Table 1. LC-MUFAs derived from saury oil were
obtained from Nippon Suisan Kaisha, Ltd. (Tokyo,
Japan); the preparation contained 58% LC-MUFAs (20:1
and 22:1 isomers combined), and the content of EPA
(C20:5 n-3) and DHA (C22:6 n-3) combined was below
1%. Following the acclimatization period, the KK-Ay
mice were randomly assigned to two groups for an 8-
week feeding experiment. The control group (n = 10)
was fed an AIN-93G growth diet (Oriental Yeast Co.,
Ltd.) containing 7% soybean oil, and the LC-MUFA
group (n = 10) was fed an LC-MUFA–supplemented diet
(3% soybean oil plus 4% LC-MUFA concentrate). The
compositions of the experimental diets are shown in
Table 2. All diet feeds were stored at −20°C and were
provided fresh daily to the mice. Body weight and food
intake were monitored throughout the study.
At the end of the intervention period at week 8,
mice were anesthetized with 4% sodium pentobarbital
(Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan)
in the early light phase of the light–dark cycle (fed condi-
tion). Blood was taken from the abdominal aorta, and
plasma was obtained by centrifugation at 3000 rpm for
15 min and stored at −80°C until further analysis. White
adipose tissue (WAT) including epididymal, mesenteric,
and subcutaneous WAT was collected and weighed, and
the body fat content [(epididymal WAT+mesenteric
WAT + subcutaneous WAT)/body weight] was calculated.
An aliquot of liver, mesenteric and subcutaneous WAT
segments was snap-frozen in liquid nitrogen and stored at
−80°C until analysis for either gene expression or lipid
profile, and another aliquot of mesenteric WAT segments
was fixed overnight at 4°C with a 4% paraformaldehyde
Table 2 Diet composition (g/100 g diet)
Ingredient Soybean oil diet (control) LC-MUFA diet
Casein 20 20
L-Cysteine 0.3 0.3
Corn starch 49.9 49.9
Sucrose 10 10
Cellulose 5 5
Mineral mixture 3.5 3.5
Vitamin mixture 1 1
Choline bitartrate 0.3 0.3
Soybean oil 7 3
LC-MUFA concentrate — 4
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metric analysis.Biochemical analysis of plasma
Plasma concentrations of total cholesterol, triglycerides,
free fatty acids (FFAs), and glucose were measured using a
Cholesterol E-Test, a Triglyceride E-Test, an NEFA C-
Test, and a Glucose CII-Test, respectively (Wako Pure
Chemical Industries, Ltd., Osaka, Japan). Plasma levels
of insulin and leptin were determined using an Insulin
ELISA kit and a Leptin ELISA kit, respectively (Morinaga





Anti-sense 50-CACCAGTGATGATGCCATTCT-30Determination of hepatic lipid levels
Hepatic lipids were extracted from the liver according to
Folch et al. [24]. The dried lipid residues were dissolved
in 2-propanol containing 10% (w/w) Triton X-100 for
the triglycerides and cholesterol assays. The hepatic tri-
glycerides and cholesterol contents were measured with
a triglyceride kit (Triglyceride E-Test; Wako) and a chol-










Cd36: fatty acid translocase (FAT)/CD36; Cpt1a: carnitine palmitoyltransferase-
1a; Cs: citrate synthase; Fatp: fatty acid transport protein; Lpl: lipoprotein lipase;
Pparg: peroxisome proliferator-activated receptor gamma; Saa3: serum
amyloid A 3.Morphometric analysis of adipocytes
Excised mesenteric WAT was stored in 4% paraformal-
dehyde and then embedded in paraffin. WAT was cut
into 10-μm sections that were fixed and stained with
hematoxylin and eosin. The sections were viewed at
20×magnification, and images were captured with an
Olympus QImaging micropublisher camera. Total adi-
pocyte number was counted manually in five random
fields for three different mice per group. Adipocyte
size was calculated based on the total adipocyte num-
ber per square millimeter of adipose tissue area, and
the result is expressed as the mean of adipocyte size
within observed fields.RNA isolation and quantitative real-time reverse
transcription polymerase chain reaction (QPCR)
RNA samples isolated from mesenteric or subcutaneous
WAT using TRIzol reagent (Qiagen K.K., Tokyo, Japan)
were reverse-transcribed to cDNA using a PrimeScript II
1st Strand cDNA Synthesis kit (Takara Bio Inc., Otsu,
Japan). The resulting cDNA pool was used for QPCR
amplification and specific sequence detection on an
Applied Biosystems 7500 Real-Time PCR System (Life
Technologies Japan Ltd., Tokyo, Japan). The primers
sequences are shown in Table 3. Gene expression was
scaled to the expression of the housekeeping gene en-
coding 18S ribosomal RNA.Plasma and WAT fatty acid composition analysis
Lipids were extracted from plasma and mesenteric WAT
samples using the method as described [25]. In brief, lipids
were extracted by homogenizing the tissue samples in a
4:1 (v/v) methanol/hexane solution supplemented with
butylated hydroxytoluene as an antioxidant. Fatty acid me-
thyl esters were obtained by transmethylation of the lipids
with acetyl chloride and heating at 80°C for 1 h under
a nitrogen atmosphere. Gas chromatographic analysis
of fatty acid methyl esters was performed on an Agilent
6890 N Network Gas Chromatograph System (Agilent
Technologies Japan, Ltd., Tokyo, Japan). Fatty acids were
identified by comparison of retention times with those of
purified standards including Nu-Chek Prep 462 (Elysian,
MN, USA) and polyunsaturated fatty acid (PUFA) No. 1,
Marine Source (Sigma-Aldrich, St. Louis, MO, USA).
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Results are expressed as mean ± SE. Student's t-test was
used for the statistical analysis. Values were considered
to be significantly different when the p value was less
than 0.05.Results
Effect of LC-MUFAs on body and organ weights and body
fat content
As shown in Table 4, there were no significant differ-
ences in food intake and body weight between the con-
trol and the LC-MUFA groups. However, dietary
treatment with LC-MUFAs for 8 weeks decreased epi-
didymal WAT, mesenteric WAT, subcutaneous WAT,
and the body fat content of mice by 10.9% (p < 0.05),
8.9% (p = 0.1), 31.2% (p < 0.01), and 16.2% (p < 0.01), re-
spectively. Despite the difference in liver weights (con-
trol: 4.0 ± 0.1 g/100 g BW vs. LC-MUFA diet: 4.8 ± 0.2 g/
100 g BW; p < 0.05), there were no differences between
diet groups in hepatic triglyceride and total cholesterol
contents.Effect of LC-MUFAs on plasma metabolites and hormones
The effects of dietary LC-MUFA treatment on circulat-
ing concentrations of total cholesterol, triglycerides,
FFAs, glucose, insulin, and leptin are shown in Table 4.Table 4 Effect of LC-MUFAs on body weight, body fat




Food intake (g/day) 4.4 ± 0.3 4.4 ± 0.2
Initial body mass (g) 29.9 ± 0.4 29.5 ± 0.5
Final body mass (g) 42.4 ± 0.8 40.1 ± 1.1
Epididymal WAT (g/100 g BW) 4.6 ± 0.2 4.1 ± 0.2*
Mesenteric WAT (g/100 g BW) 2.7 ± 0.1 2.4 ± 0.1
Subcutaneous WAT(g/100 g BW) 3.2 ± 0.3 2.2 ± 0.2**
Body fat contents (g/100 g BW) 10.5 ± 0.4 8.8 ± 0.3**
Liver (g/100 g BW) 4.0 ± 0.1 4.8 ± 0.2*
Hepatic triglyceride (mg/g Liver) 60.5 ± 4.8 68.7 ± 2.7
Hepatic total cholesterol (mg/g Liver) 4.0 ± 0.6 3.8 ± 0.4
Plasma total cholesterol (mg/dL) 180.4 ± 7.3 156.4 ± 8.2*
Plasma triglycerides (mg/dL) 204.4 ± 13.5 220.4 ± 21.3
Plasma FFAs (μEq/mL) 696.4 ± 25 553.8 ± 30.7**
Plasma glucose (mg/dL) 486.4 ± 30.1 475.6 ± 42.3
Plasma insulin (ng/mL) 82.8 ± 8.9 61 ± 4.1*
Plasma leptin (ng/mL) 19.4 ±0.7 16.3 ±0.7*
Each value represents the mean ± SE (n = 10). BW: body weight; FFAs: free
fatty acids; WAT: white adipose tissue; Body fat contents: (epididymal adipose
tissue +mesenteric adipose tissue + subcutaneous adipose tissue)/body
weight. * p < 0.05; ** p < 0.01 compared with the control group.LC-MUFAs significantly decreased plasma levels of total
cholesterol by 13.3% (p < 0.05), FFAs by 20.5% (p < 0.01),
insulin by 26.3% (p < 0.05), and leptin by 15.9 (p < 0.05),
although plasma levels of triglycerides and glucose did
not significantly differ between the LC-MUFA and con-
trol groups.
Effect of LC-MUFAs on adipocyte size
Compared with the control, adipocyte size in the LC-
MUFA group notably decreased (p < 0.05; Figure 1). Adi-
pocytes from the LC-MUFA group were ~16% smaller
than adipocytes from the control group.
Effect of LC-MUFAs on mRNA expression of peroxisome
proliferator-activated receptor gamma (Pparg) target
genes in adipose tissues
To explore the potential molecular mechanism of redu-
cing fat pad weight and obesity-related metabolic dys-
function by LC-MUFAs, the expression of the gene
encoding Pparg and its target genes in mesenteric and
subcutaneous WAT was determined by QPCR. The LC-
MUFA–supplemented diet upregulated the expression
of Pparg, Lpl (lipoprotein lipase), and Cd36 (fatty acidFigure 1 Adipocyte size in KK-Ay mice fed the control diet or
LC-MUFA diet for 8 weeks. Mesenteric WAT sections were stained
with hematoxylin and eosin (A), and adipocyte diameters were
measured (B). The diameters of adipocytes are presented as mean
values for a 1-mm2 area of WAT section. Values represent the
mean ± SE, n = 5. *p < 0.05 compared with the control group.
Figure 2 mRNA expression of Pparg target genes in adipose
tissue of KK-Ay mice fed the control diet or LC-MUFA diet for
8 weeks. Expression of the gene encoding peroxisome proliferator-
activated receptor gamma (Pparg) and its target genes lipoprotein
lipase (Lpl), fatty acid transport protein (Fatp), and fatty acid
translocase/CD36 (Cd36) in adipose tissues was quantified by QPCR
analysis. (A) Mesenteric WAT, (B) subcutaneous WAT. Values
represent the mean ± SE, n = 10. *p < 0.05, **p < 0.01 compared with
the control group.
Figure 3 mRNA expression of genes involved in lipid oxidation
in adipose tissue of KK-Ay mice fed the control diet or LC-
MUFA diet for 8 weeks. Expression of carnitine palmitoyltransferase
1a (Cpt1a) and citrate synthase (Cs) in adipose tissues were
quantified by QPCR analysis. (A) Mesenteric WAT, (B) subcutaneous
WAT. Values represent the mean ± SE, n = 10. *p < 0.05 compared
with the control group.
Yang et al. Nutrition & Metabolism 2013, 10:16 Page 5 of 10
http://www.nutritionandmetabolism.com/content/10/1/16translocase/CD36) mRNA by 160% (p < 0.05), 280%
(p < 0.01), and 92% (p < 0.05), respectively, in mesenteric
WAT (Figure 2A). LC-MUFA intake also upregulated
the expression of Pparg, Lpl, Fatp (fatty acid transport
protein), and Cd36 mRNA by 110% (p < 0.05), 190%
(p < 0.05), 280% (p < 0.01), and 140% (p < 0.05), respect-
ively, in subcutaneous WAT (Figure 2B).
Effect of LC-MUFAs on mRNA expression of genes
involved in lipid oxidation in adipose tissues
Intake of LC-MUFAs increased expression of Cpt1a (carni-
tine palmitoyltransferase 1a) by 180% (p < 0.05) and CS
(citrate synthase) by 95.4% (p < 0.05) in mesenteric WAT
(Figure 3A). Similarly, LC-MUFA intake upregulated
expression of Cpt1a mRNA by 120% (p < 0.05) in subcuta-
neous WAT (Figure 3B).Effect of LC-MUFAs on mRNA expression of inflammatory
marker gene in adipose tissues
To investigate whether LC-MUFAs reduce adipose in-
flammation in KK-Ay mice, we measured mRNA expres-
sion of Saa3 (serum amyloid A 3) in adipose tissues. As
shown in Figure 4, LC-MUFA diet decreased expression
of Saa3 by 60% (p < 0.05) in mesenteric WAT (Figure 4A),
and by 52% (p < 0.05) in subcutaneous WAT (Figure 4B).
Effect of LC-MUFAs on fatty acid composition of plasma,
liver, and WAT
As shown in Table 5, the percentage of LC-MUFAs (C20:1
and C22:1 combined) as well as total MUFAs significantly
increased in the LC-MUFA group in plasma and liver of
KK-Ay mice after treatment for 8 weeks. In the LC-MUFA
group, the combined levels of C20:1 and C22:1 isomers in
plasma and liver increased by 370% (p < 0.001) and 200%
Figure 4 mRNA expression of inflammatory marker gene in
adipose tissues of KK-Ay mice fed the control diet or LC-MUFA
diet for 8 weeks. Expression of serum amyloid A 3 (Saa3) in
adipose tissues were quantified by QPCR analysis. (A) Mesenteric
WAT, (B) subcutaneous WAT. Values represent the mean ± SE, n = 10.
*p < 0.05 compared with the control group.
Table 5 Effect of LC-MUFAs on fatty acid composition (%)
in plasma and liver in KK-Ay mice








14:0 0.19 ± 0.04 0.30 ± 0.02* 0.38 ± 0.06 0.56 ± 0.02*
16:0 21.68 ± 0.59 20.34 ± 0.49 22.11 ± 0.32 23.62 ± 0.60*
18:0 12.05 ± 0.69 9.31 ± 0.41** 6.12 ± 0.34 4.36 ± 0.24***
20:0 0.35 ± 0.04 0.35 ± 0.01 0.41 ± 0.02 0.39 ± 0.02
SFA 34.26 ± 0.96 30.31 ± 0.73** 29.02 ± 0.38 28.94 ± 0.61
16:1 n-7 1.57 ± 0.26 2.61 ± 0.22** 3.51 ± 0.20 5.14 ± 0.39**
18:1 n-9 12.21 ± 1.62 17.84 ± 0.79** 28.74 ± 1.11 36.23 ± 1.01***
18:1 n-7 2.41 ± 0.19 2.99 ± 0.13* 3.68 ± 0.19 4.67 ± 0.22**
20:1 n-11 ND 0.73 ± 0.06*** ND 1.27 ± 0.07***
20:1 n-9 0.41 ± 0.05 0.74 ± 0.02*** 0.78 ± 0.03 0.91 ± 0.04*
22:1 n-11 ND 0.48 ± 0.09** ND 0.36 ± 0.03***
22:1 n-9 0.01 ± 0.01 0.03 ± 0.01 0.12 ± 0.01 0.17 ± 0.01**
LC-MUFA 0.42 ± 0.06 1.97 ± 0.18*** 0.90 ± 0.03 2.70 ± 0.13***
MUFA 16.61 ± 2.06 25.39 ± 0.92** 36.83 ± 1.37 48.74 ± 0.98***
18:2 n-6 26.71 ± 1.11 22.37 ± 0.47** 18.43 ± 0.73 10.01 ± 0.46***
18:3 n-6 0.27 ± 0.03 0.32 ± 0.01 0.20 ± 0.01 0.13 ± 0.01***
20:2 n-6 0.32 ± 0.04 0.26 ± 0.01 0.25 ± 0.03 0.12 ± 0.01***
20:3 n-6 1.35 ± 0.09 1.52 ± 0.07 0.62 ± 0.03 0.48 ± 0.03**
20:4 n-6 9.98 ± 1.17 6.61 ± 0.44*** 5.11 ± 2.71 2.71 ± 0.24***
n-6 PUFA 38.62 ± 1.71 31.08 ± 0.56** 24.61 ± 0.97 13.44 ± 0.57***
18:3 n-3 0.89 ± 0.06 0.53 ± 0.05*** 1.10 ± 0.04 0.41 ± 0.03***
20:5 n-3 0.62 ± 0.07 1.39 ± 0.04*** 0.32 ± 0.03 0.39 ± 0.03
22:5 n-3 0.42 ± 0.06 0.54 ± 0.02 0.10 ± 0.01 0.19 ± 0.02**
22:6 n-3 5.42 ± 0.37 6.08 ± 0.32 3.33 ± 0.20 2.69 ± 0.20*
n-3 PUFA 7.32 ± 0.28 8.54 ± 0.27** 4.85 ± 0.25 3.67 ± 0.22**
n-3/n-6 0.19 ± 0.01 0.27 ± 0.01*** 0.20 ± 0.01 0.27 ± 0.01***
Each value represents the mean ± SE (n = 10). ND: Not detected; WAT: white
adipose tissue; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids;
LC-MUFA: long-chain monounsaturated fatty acids (C20:1 and C22:1 isomers
combined); PUFA: polyunsaturated fatty acids; * p < 0.05; ** p < 0.01; ***
p < 0.001 compared with the control group.
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linoleic acid (C18:2 n-6) levels significantly in plasma and
liver by 16% (p < 0.01) and 45.7% (p < 0.001), respectively,
and accordingly decreased total n-6 PUFA levels signifi-
cantly in plasma and liver by 19.5% (p < 0.01) and 45.4%
(p < 0.001), respectively. Compared to the control group,
the plasma levels of EPA and total n-3 PUFA levels
increased significantly in the LC-MUFA diet group by
132.1% (p < 0.001) and 16.1% (p < 0.01), respectively. In
contrast, LC-MUFA diet decreased DHA and total n-3
PUFA levels by 19.2% (p < 0.05) and 24.3% (p < 0.01).
Nevertheless, LC-MUFA diet increased plasma and liver
n-3/n-6 ratio by 42% (p < 0.001) and 35% (p < 0.001),
respectively.
Table 6 shows fatty acid compositions in adipose
tissues including mesenteric WAT and subcutaneousWAT with soybean oil diet and LC-MUFA diet.
LC-MUFA diet increased LC-MUFAs in mesenteric
WAT by 740% (p < 0.001), and those in subcutaneous
WAT by 883% (p < 0.001). In contrast, LC-MUFA diet
decreased total n-6 and n-3 PUFA levels in both mesen-
teric WAT and subcutaneous WAT. In the LC-MUFA
group, total n-6 PUFA levels in mesenteric WAT and sub-
cutaneous WAT decreased by 45.8% (p < 0.001) and 42%
(p < 0.001), respectively. With LC-MUFA diet, total n-3
PUFA levels in mesenteric WAT and subcutaneous WAT
decreased by 48.1% (p < 0.001) and 49.3% (p < 0.001),
respectively.
Table 6 Effect of LC-MUFAs on fatty acid composition (%)
in mesenteric and subcutaneous WAT in KK-Ay mice








14:0 0.81 ± 0.02 1.18 ± 0.02* 0.76 ± 0.09 1.31 ± 0.15* *
16:0 18.92 ± 0.27 20.97 ± 0.41** 15.42 ± 0.22 16.29 ± 0.98
18:0 2.31 ± 0.21 2.26 ± 0.09 1.45 ± 0.38 1.18 ± 0.42
20:0 0.10 ± 0 0.11 ± 0.01 0.08 ± 0 0.12 ± 0.01
SFA 22.13 ± 0.37 24.53 ± 0.43** 17.72 ± 0.31 18.90 ± 0.43
16:1 n-7 4.42 ± 0.21 5.24 ± 0.41 6.27 ± 0.89 7.27 ± 1.54
18:1 n-9 31.19 ± 0.39 35.68 ± 0.45*** 30.06 ± 0.64 35.88 ± 0.85***
18:1 n-7 2.46 ± 0.13 3.03 ± 0.05** 2.64 ± 0.20 2.99 ± 0.39*
20:1 n-11 0.08 ± 0 3.03 ± 0.11*** 0.05 ± 0 3.14 ± 0.32***
20:1 n-9 0.56 ± 0.01 1.27 ± 0.04*** 0.48 ± 0.04 1.29 ± 0.09***
22:1 n-11 ND 1.29 ± 0.06*** ND 1.36 ± 0.19***
22:1 n-9 0.04 ± 0 0.13 ± 0.01*** 0.03 ± 0 0.14 ± 0.02***
LC-MUFA 0.68 ± 0.01 5.72 ± 0.21*** 0.57 ± 0.01 5.94 ± 0.19***
MUFA 38.63 ± 0.49 49.67 ± 0.91*** 39.54 ± 0.38 52.07 ± 0.71***
18:2 n-6 33.58 ± 0.52 20.14 ± 0.52*** 33.89 ± 0.98 19.62 ± 1.69***
18:3 n-6 0.05 ± 0 0.04 ± 0.01 0.06 ± 0 0.07 ± 0.01*
20:2 n-6 0.13 ± 0 0.09 ± 0.01*** 0.11 ± 0.01 0.08 ± 0.01***
20:3 n-6 0.05 ± 0 0.04 ± 0* 0.06 ± 0 0.04 ± 0.01**
20:4 n-6 0.11 ± 0.01 0.09 ± 0.01 0.13 ± 0.01 0.09 ± 0.02***
n-6 PUFA 33.92 ± 0.52 18.37 ± 0.71*** 34.26 ± 0.31 19.91 ± 0.63***
18:3 n-3 2.09 ± 0.22 1.09 ± 0.05** 2.64 ± 0.14 1.19 ± 0.10***
20:5 n-3 0.03 ± 0 0.01 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
22:5 n-3 0.01 ± 0 0.01 ± 0 0.01 ± 0.01 0.02 ± 0.01
22:6 n-3 0.04 ± 0 0.14 ± 0.01*** 0.04 ± 0.01 0.14 ± 0.02***
n-3 PUFA 2.16 ± 0.22 1.12 ± 0.14*** 2.72 ± 0.05 1.38 ± 0.04***
n-3/n-6 0.06 ± 0.01 0.06 ± 0 0.08 ± 0 0.07 ± 0
Each value represents the mean ± SE (n = 10). ND: Not detected; WAT: white
adipose tissue; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids;
LC-MUFA: long-chain monounsaturated fatty acids (C20:1 and C22:1 isomers
combined); PUFA: polyunsaturated fatty acids; * p < 0.05; ** p < 0.01; ***
p < 0.001 compared with the control group.
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It is well established that patients with type 2 DM often
have a co-occurrence of insulin resistance, hyperinsuline-
mia, hyperglycemia, dyslipidemia, and/or obesity [26-28].
In the present study, we showed that dietary administration
of LC-MUFAs for 8 weeks attenuated hyperinsulinemia
and hyperlipidemia and decreased fat pad weight in diabetic
KK-Ay mice.
Insulin resistance has been assigned a central place in the
metabolic disturbances associated with obesity and type 2
DM, and compensatory hyperinsulinemia stemming from
peripheral insulin resistance is a well-recognized metabolic
disturbance in type 2 DM [29-31]. Furthermore, it has beendemonstrated that mice transfected with extra copies of the
insulin gene produce elevated insulin levels, and they show
insulin resistance, hyperglycemia, and hypertriglyceridemia,
suggesting that insulin itself is an important contributor to
insulin resistance [32]. Besides hyperinsulinemia, obesity-
derived hyperlipidemia is one of the suggested possible
mechanisms for type 2 DM. Serum FFAs, which are ele-
vated in most obese subjects, induce metabolic insulin re-
sistance and inhibit insulin signaling through different
mechanisms [33,34]. The LC-MUFA diet decreased plasma
insulin and FFA concentrations that were markedly ele-
vated in spontaneous type 2 diabetic KK-Ay mice, suggest-
ing that treatment of diabetic mice with LC-MUFAs may
favorably impact the risk factors for type 2 DM. On the
other hand, non-fasting levels of plasma triglycerides and
glucose were not significantly different between the control
and LC-MUFA diet group. It is therefore suggested that the
antidiabetic effect of LC-MUFAs in KK-Ay mice was mild.
In addition, although there were no significant differences
in hepatic triglycerides and total cholesterol, LC-MUFA
intake increased liver weight. It is not yet clear whether this
is due to the changes in the fatty acid composition of the
liver with LC-MUFA administration, and further studies
are needed to address whether LC-MUFAs have any impact
on liver health and fatty liver in particular.
Because type 2 DM is closely associated with obe-
sity, ~80–90% of people diagnosed with type 2 DM are
also diagnosed as being overweight or obese, and several
studies of human subjects have shown that the risk of
developing DM is reduced by weight loss [35,36]. Research
suggests that adipose tissue not only serves as a storage site
for fat but also functions as an endocrine organ [37,38].
Adipose tissue grows by two mechanisms: hyperplasia and
hypertrophy, the latter occurring prior to hyperplasia to
meet the need for additional fat storage capacity as obesity
progresses [39]. In fact, obesity is characterized by adipo-
cyte hypertrophy followed by increased angiogenesis, im-
mune cell infiltration, extracellular matrix overproduction,
and, consequently, by increased production of proinflam-
matory adipocytokines and FFAs, which are potentially
involved in the pathogenesis of insulin resistance. In the
present study, whereas there were no differences in body
weight gain between the LC-MUFA group and control
group, dietary treatment of KK-Ay mice with LC-MUFAs
reduced fat accumulation and caused decreased adipocyte
size, which may in turn have improved lipid metabolism
and attenuated compensatory hyperinsulinemia. The LC-
MUFA diet increased plasma and organ levels of C20:1 and
C22:1 isomers, suggesting a negative correlation between
LC-MUFA intake and risk factors for type 2 DM in KK-Ay
mice. Plasma, liver and WAT levels of linoleic acid (C18:2
n-6), a major fatty acid in soybean oil used in the control
diet, decreased significantly in mice fed the LC-MUFA diet,
however, suggesting a minor role for linoleic acid in the
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Worthy of note, the predominant LC-MUFA isomers in
the current study is C22:1 n-11, an isomer of erucic acid
(C22:1 n-9) which is an important fatty acid of rapeseed oil,
and LC-MFUA diet increased plasma and organ levels of
C22:1 n-11 significantly. Given that there is continuing
controversy as to the health effects of erucic acid [40-42],
further study is required to examine the physiologic simi-
larities and differences between the C22:1 isomers. Further-
more, LC-MUFA diet increased palmitoleic acid (C16:1
n-7) levels in plasma and liver significantly, and in adipose
tissues non-significantly (p < 0.15). Although it has been
proposed some beneficial effects of palmitoleic aicd in cell
culture and animal models [43,44], human plasma palmito-
leic acid content has been reported to be a consistent and
independent predictor in incident diabetes [45,46]. It is
therefore suggested that no all MUFAs are uniformly bene-
ficial, and we could not exclude the possibility that a rise in
palmitoleic acid with LC-MUFA diet could have some
potential negative implications in a diabetic animal model.
To explore the potential positive impact of reducing adi-
pocyte size and lowering plasma FFAs, we evaluated the
expression of Pparg, Lpl, Fatp, and Cd36 mRNA in adi-
pose tissue. Pparg, which is expressed predominantly in
adipose tissue, plays crucial roles in regulating adipocyte
differentiation, fatty acid metabolism, and insulin signal
transduction [47,48]. Overexpression of Pparg in mature
3T3-L1 adipocytes results in a decrease in both cell size
and intracellular triglyceride content, and Pparg activation
results in a marked improvement of insulin and glucose
parameters resulting from an improvement of whole-body
insulin sensitivity in type 2 diabetic patients [49-51]. The
Pparg target genes Lpl, Fatp, and Cd36 are important con-
trol elements in FFA homeostasis [52,53]. FFAs liberated
from circulating lipoproteins through hydrolysis by LPL
bind to albumin, and cell surface receptors such as Fatp
and Cd36 facilitate rapid uptake and coordinate the im-
port of FFAs. Our data demonstrate that Pparg mRNA
level increased in adipose tissue of KK-Ay mice fed LC-
MUFAs, which was paralleled by increases in Lpl, Fatp,
and Cd36 mRNAs, suggesting that reduction in adipocyte
size and an increase in FFA uptake in adipose tissue were
partly attributed to upregulation of Pparg and its target
genes, Lpl, Fatp, and Cd36. Furthermore, concomitant
with increase in Pparg gene expression, plasma leptin
levels were decreased with the LC-MUFA diet. Leptin, a
16 KDa protein hormone that plays a key role in regulat-
ing adipose tissue mass and energy balance, is secreted
primarily by adipocytes [54]. Circulating leptin levels are
highly correlated with body fat stores, and high plasma
leptin levels are observed in obese subjects as a result of
increased production in enlarged fat cells [55]. Studies
have demonstrated that leptin is located at Pparg down-
stream, and Pparg activation inhibits leptin genetranscription [56]. It is therefore suggested that LC-
MUFAs decreased plasma leptin levels may possibly
through activating Pparg in adipose. Furthermore, it has
been demonstrated that adipose inflammation plays key
roles in the vascular complications of obesity, insulin re-
sistance, as well as type 2 DM, and hypertrophic adipo-
cytes within adipose tissue directly augment systemic
inflammation [57]. The present study shows that LC-
MUFA feeding downregulated the expression of inflam-
matory marker Saa3 in adipose tissue with concomitant
decreases in adipocyte size. These results suggest possible
mechanisms for the beneficial effects of a LC-MUFA-rich
diet.
Insulin resistance in subjects with type 2 DM and obes-
ity is connected with an imbalance between the availability
and the oxidation of lipids [58]. Cpt1a and Cs are asso-
ciated with fatty acid utilization and oxidation capacity
[59,60], and the increase in Cpt1a and Cs expression
observed in the current study was possibly related to the
elevated uptake of circulating FFAs by adipose tissue.
Studies have shown that inhibition of Cpt1a increases lipid
deposition and exacerbates insulin resistance when ani-
mals are placed on a high-fat diet, whereas overexpression
of Cpt1a protects myotubes against lipid-induced insulin
resistance [61-63]. The present study suggests that a diet
supplemented with LC-MUFAs may promote fatty acid
oxidation by upregulating Cpt1a and Cs expression, which
is possibly associated with a diminution of risk factors for
type 2 DM.
Conclusions
In conclusion, dietary treatment of KK-Ay mice with LC-
MUFAs improved their diabetic condition. Fat pad weight
as well as adipocyte size, hyperlipidemia, hyperinsuline-
mia, and hyperleptinemia were reduced in response to the
LC-MUFA diet, most likely partly attributable to upregu-
lation of Pparg and its target genes. An increase in LC-
MUFA levels in plasma and WAT following consumption
of an LC-MUFA diet is likely to be involved in the
observed beneficial changes to metabolic indicators.
Abbreviations
Cd36: Fatty acid translocase; Cpt1a: Carnitine palmitoyltransferase-1a;
Cs: Citrate synthase; DM: Diabetes mellitus; Fatp: Fatty acid transport protein;
FFA: Free fatty acid; LC-MUFA: Long-chain monounsaturated fatty acid;
Lpl: Lipoprotein lipase; PUFA: Polyunsaturated fatty acid; Pparg: Peroxisome
proliferator-activated receptor gamma; QPCR: Quantitative real-time
polymerase chain reaction; Saa3: Serum amyloid A 3.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZHY participated in the planning, analysis, and manuscript preparation. HM
and YI participated in the experimental work. JT and MK participated in the
planning and organization of the study. All authors read and approved the
final manuscript.
Yang et al. Nutrition & Metabolism 2013, 10:16 Page 9 of 10
http://www.nutritionandmetabolism.com/content/10/1/16Received: 19 December 2012 Accepted: 27 January 2013
Published: 30 January 2013References
1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the
diabetes epidemic. Nature 2001, 414:782–787.
2. King H, Aubert RE, Herman WH: Global burden of diabetes 1995–2025:
prevalence, numerical estimates, and projections. Diabetes Care 1998,
21:1414–1431.
3. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H,
Thompson TJ: Projection of diabetes burden through 2050: impact of
changing demography and disease prevalence in the U.S. Diabetes Care
2001, 24:1936–1940.
4. Cheng D: Prevalence, predisposition and prevention of type II diabetes.
Nutr Metab 2005, 2:29.
5. Hulbert AJ, Turner N, Storlien LH, Else PL: Dietary fats and membrane
function: implications for metabolism and disease. Biol Rev Camb Philos
Soc 2005, 80:155–169.
6. Abete I, Goyenechea E, Zulet MA, Martínez JA: Obesity and metabolic
syndrome: potential benefit from specific nutritional components. Nutr
Metab Cardiovasc 2011, Suppl 2:B1–B15.
7. Bergouignan A, Momken I, Schoeller DA, Simon C, Blanc S: Metabolic fate
of saturated and monounsaturated dietary fats: the Mediterranean diet
revisited from epidemiological evidence to cellular mechanisms. Prog
Lipid Res 2009, 48:128–147.
8. Gillingham LG, Harris-Janz S, Jones PJ: Dietary monounsaturated fatty
acids are protective against metabolic syndrome and cardiovascular
disease risk factors. Lipids 2011, 46:209–228.
9. Kien CL: Dietary interventions for metabolic syndrome: role of modifying
dietary fats. Curr Diab Rep 2009, 9:43–50.
10. Matthan NR, Dillard A, Lecker JL, Ip B, Lichtenstein AH: Effects of dietary
palmitoleic acid on plasma lipoprotein profile and aortic cholesterol
accumulation are similar to those of other unsaturated fatty acids in the
F1B golden Syrian hamster. J Nutr 2009, 139:215–221.
11. Bang HO, Dyerberg J, Sinclair HM: The composition of the Eskimo food in
north western Greenland. Am J Clin Nutr 1980, 33:2657–2661.
12. Dyerberg J, Bang HO, Hjorne N: Fatty acid composition of the plasma
lipids in Greenland Eskimos. Am J Clin Nutr 1975, 28:958–966.
13. Ota T, Takagi T, Kosaka S: Changes in lipids of young and adult saury
cololabis saira (Pisces). Mar Ecol Prog Ser 1980, 3:11–17.
14. Pascal JC, Ackman RG: Long-chain monoethylenic alcohol and acid
isomers in lipids of copepods and capelin. Chem Phys Lipids 1976,
16:219–223.
15. Hardy R, Mackie P: Seasonal variation in some of the lipid components of
sprats (Sprattus sprattus). J Sci Food Agric 1969, 20:193–198.
16. Ratnayake WN, Ackman RG: Fatty alcohols in capelin, herring and
mackerel oils and muscle lipids: I fatty alcohol details linking dietary
copepod fat with certain fish depot fats. Lipids 1979, 14:795–803.
17. Graeve M, Kattner G: Species-specific differences in intact wax esters of
Calanus hyperboreus and C. finmarchicus from Fram Strait-Greenland Sea.
Mar Chem 1992, 39:269–281.
18. Falk-Petersen S, Sargent JR, Tande KS: Lipid composition of zooplankton in
relation to the sub-arctic food web. Polar Biol 1987, 8:115–120.
19. Yang ZH, Miyahara H, Takemura S, Hatanaka A: Dietary saury oil reduces
hyperglycemia and hyperlipidemia in diabetic KKAy mice and in diet-
induced obese C57BL/6 J mice by altering gene expression. Lipids 2011,
46:425–434.
20. Yang ZH, Miyahara H, Takeo J, Hatanaka A, Katayama M: Pollock oil
supplementation modulates hyperlipidemia and ameliorates hepatic
steatosis in mice fed a high-fat diet. Lipids Health Dis 2011, 10:189.
21. Yang ZH, Miyahara H, Mori T, Doisaki N, Hatanaka A: Beneficial effects of
dietary fish-oil-derived monounsaturated fatty acids on metabolic
syndrome risk factors and insulin resistance in mice. J Agric Food Chem
2011, 59:7482–7489.
22. Iwatsuka H, Shino A, Suzuoki Z: General survey of diabetic features of
yellow KK mice. Endocrinol Jpn 1970, 17:23–35.
23. Castle CK, Colca JR, Melchior GW: Lipoprotein profile characterization of
the KKA(y) mouse, a rodent model of type II diabetes, before and after
treatment with the insulin-sensitizing agent pioglitazone. Arterioscler
Thromb 1993, 13:302–309.24. Folch J, Lees M, Stanley GHS: A simple method for the isolation and
purification of total lipids from animal tissues. J Biol Chem 1956,
226:497–509.
25. Lepage G, Roy CC: Direct transesterification of all classes of lipids in a
one-step reaction. J Lipid Res 1986, 27:114–120.
26. Mooradian AD: Nat Dyslipidemia in type 2 diabetes mellitus. Clin Pract
Endocrinol Metab 2009, 5:150–159.
27. Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal
adiposity on the development of cardiovascular disease and diabetes
mellitus. Am J Med 2007, 120:S12–S18.
28. Choi K, Kim YB: Molecular mechanism of insulin resistance in obesity and
type 2 diabetes. Korean J Intern Med 2010, 25:119–129.
29. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose
removal and hyperinsulinemia precede the development of type II
diabetes in the offspring of diabetic parents. Ann Intern Med 1990,
113:909–915.
30. Vaag A, Henrikssen JE, Beck-Nielsen H: Decreased insulin activation of
glycogen synthesis in skeletal muscles in young nonobese Caucasian first-
degree relatives of patients with NIDDM. J Clin Invest 1992, 89:782–788.
31. Heptulla RA, Tamborlane WV, Cavaghan M, Bronson M, Limb C, Ma YZ,
Sherwin RS, Caprio S: Augmentation of alimentary insulin secretion
despite similar gastric inhibitory peptide (GIP) responses in juvenile
obesity. Pediatr Res 2000, 47:628–633.
32. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J: Insulin resistance and
hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes
Care Suppl 2008, 2:S262–S268.
33. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW,
Shulman GI: Mechanism of free fatty acid-induced insulin resistance in
humans. J Clin Invest 1996, 97:2859–2865.
34. Delarue J, Magnan C: Free fatty acids and insulin resistance. Curr Opin Clin
Nutr Metab Care 2007, 10:142–148.
35. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH:
Prevalence of obesity in type 2 diabetes in secondary care: association
with cardiovascular risk factors. Postgrad Med J 2006, 82:280–284.
36. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J, Grant AM:
Weight loss in obese diabetic and non-diabetic individuals and long-
term diabetes outcomes–a systematic review. Diabetes Obes Metab 2004,
6:85–94.
37. Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients
and inflammation. J Clin Invest 2008, 118:2992–3002.
38. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006,
444:860–867.
39. Faust IM, Johnson PR, Stern JS, Hirsh J: Diet-induced adipocyte number
increase in adult rats: a new model of obesity. Am J Physiol 1978,
235:279–286.
40. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME,
Jennings SS, Davis S, Jaitly R, Sgro JA: Dietary erucic acid therapy for
X-linked adrenoleukodystrophy. Neurology 1989, 39:1415–1422.
41. Asano J, Suzuki Y, Yajima S, Inoue K, Shimozawa N, Kondo N, Murase M, Orii
T: Effects of erucic acid therapy on Japanese patients with X-linked
adrenoleukodystrophy. Brain Dev 1994, 16:454–458.
42. Borg K: Physiopathological effects of rapeseed oil: a review. Acta Med
Scand Suppl 1975, 585:5–13.
43. Morgan NG, Dhayal S: Unsaturated fatty acids as cytoprotective agents in
the pancreatic beta-cell. Prostaglandins Leukot Essent Fatty Acids 2010,
82:231–236.
44. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS:
Identification of a lipokine, a lipid hormone linking adipose tissue to
systemic metabolism. Cell 2008, 134:933–944.
45. Lindgärde F, Vessby B, Ahrén B: Serum cholesteryl fatty acid composition
and plasma glucose concentrations in Amerindian women. Am J Clin
Nutr 2006, 84:1009–1013.
46. Paillard F, Catheline D, Duff FL, Bouriel M, Deugnier Y, Pouchard M, Daubert
JC, Legrand P: Plasma palmitoleic acid, a product of stearoyl-coA
desaturase activity, is an independent marker of triglyceridemia and
abdominal adiposity. Nutr Metab Cardiovasc Dis 2008, 18:436–440.
47. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med
2002, 53:409–435.
48. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated
receptors: a nuclear receptor signaling pathway in lipid physiology. Annu
Rev Cell Dev Biol 1996, 12:335–363.
Yang et al. Nutrition & Metabolism 2013, 10:16 Page 10 of 10
http://www.nutritionandmetabolism.com/content/10/1/1649. Tamori Y, Masugi J, Nishino N, Kasuga M: Role of peroxisome proliferator-
activated receptor-gamma in maintenance of the characteristics of
mature 3T3-L1 adipocytes. Diabetes 2002, 51:2045–2055.
50. Olefsky JM, Saltiel AR: PPAR gamma and the treatment of insulin
resistance. Trends Endocrinol Metab 2000, 11:362–368.
51. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin
resistance and type 2 diabetes. Diabetes 1996, 45:1661–1669.
52. Goldberg IJ, Eckel RH, Abumrad NA: Regulation of fatty acid uptake into
tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res
2009, 50:S86–S90.
53. Schaffer JE, Lodish HF: Expression cloning and characterization of a novel
long chain faty acid transport protein. Cell 1994, 79:427–436.
54. Mantzoros CS: Leptin in relation to the lipodystrophy-associated
metabolic syndrome. Diabetes Metab J 2012, 36:181–189.
55. Lee MJ, Wang Y, Ricci MR, Sullivan S, Russell CD, Fried SK: Acute and
chronic regulation of leptin synthesis, storage, and secretion by insulin
and dexamethasone in human adipose tissue. Am J Physiol Endocrinol
Metab 2007, 292:E858–E864.
56. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob)
gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996,
93:5793–5796.
57. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular
disease. Circ Res 2005, 96:939–949.
58. Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA: Lipid oxidation is
reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab
2000, 279:E1039–E1044.
59. Stephens FB, Constantin-Teodosiu D, Greenhaff PL: New insights
concerning the role of carnitine in the regulation of fuel metabolism in
skeletal muscle. J Physiol 2007, 581:431–444.
60. Ortenblad N, Mogensen M, Petersen I, Højlund K, Levin K, Sahlin K, Beck-Nielsen
H, Gaster M: Reduced insulin-mediated citrate synthase activity in cultured
skeletal muscle cells from patients with type 2 diabetes: evidence for an
intrinsic oxidative enzyme defect. Biochim Biophys Acta 2005, 1741:206–214.
61. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD:
Prolonged inhibition of muscle carnitine palmitoyltransferase-1
promotes intramyocellular lipid accumulation and insulin resistance in
rats. Diabetes 2001, 50:123–130.
62. Sebastián D, Herrero L, Serra D, Asins G, Hegardt FG: CPT I overexpression
protects L6E9 muscle cells from fatty acid-induced insulin resistance.
Am J Physiol Endocrinol Metab 2007, 292:E677–E686.
63. Perdomo G, Commerford SR, Richard AM, Adams SH, Corkey BE, O'Doherty
RM, Brown NF: Increased beta-oxidation in muscle cells enhances insulin-
stimulated glucose metabolism and protects against fatty acid-induced
insulin resistance despite intramyocellular lipid accumulation. J Biol Chem
2004, 279:27177–27186.
doi:10.1186/1743-7075-10-16
Cite this article as: Yang et al.: Dietary supplementation with long-chain
monounsaturated fatty acids attenuates obesity-related metabolic
dysfunction and increases expression of PPAR gamma in adipose tissue
in type 2 diabetic KK-Ay mice. Nutrition & Metabolism 2013 10:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
